News
- 5th April 2024
Jadeite Medicines to initiate Phase 3 Trial of Odevixibat in Alagille Syndrome in Japan - 31st January 2024
JADEITE MEDICINES ANNOUNCES STRATEGIC COLLABORATION WITH IPSEN FOR DEVELOPMENT AND COMMERCIALIZATION OF ODEVIXIBAT IN JAPAN - 21st June 2023
Jadeite Medicines Receives Orphan Drug Designation for Odevixibat in Progressive Familial Intrahepatic Cholestasis (PFIC) from the Ministry of Health, Labour and Welfare of Japan and will also initiate Phase 3 Trial of Odevixibat in PFIC in Japan - 12th October 2021
On October 12, 2021, Jadeite Medicines Inc. and Albireo Pharma, Inc. (Currently Ipsen) announced a development agreement for odevixibat in Japan.